Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Michael A Ueberall, Stefan Lorenzl, Eberhard A Lux, Raymond Voltz & Michael Perelman. (2016) Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain. Journal of Pain Research 9, pages 571-585.
Read now
Read now
Stephen CB Lim, Michael J Paech, Bruce Sunderland & Yandi Liu. (2013) In vitro and in vivo evaluation of a sublingual fentanyl wafer formulation. Drug Design, Development and Therapy 7, pages 317-324.
Read now
Read now
Daniele Santini, Gaetano Lanzetta, Emanuela Dell'Aquila, Bruno Vincenzi, Olga Venditti, Marco Russano, Nicola Papapietro, Vincenzo Denaro, Giuseppe Tonini & Carla Ripamonti. (2013) ‘Old' and ‘new' drugs for the treatment of cancer pain. Expert Opinion on Pharmacotherapy 14:4, pages 425-433.
Read now
Read now
Eric Prommer & Brandy Ficek. (2012) Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain. Patient Preference and Adherence 6, pages 465-475.
Read now
Read now
Articles from other publishers (29)
B.Y. Cooper, T.J. Nutter, L.D. Flunker & C.M. Bowers. (2022) Combinations of classical and non-classical voltage dependent potassium channel openers suppress nociceptor discharge and reverse chronic pain signs in a rat model of Gulf War illness. NeuroToxicology 93, pages 186-199.
Crossref
Crossref
L.D. Flunker, T.J. Nutter, C.M. Bowers & B.Y. Cooper. (2021) Development of KVO treatment strategies for chronic pain in a rat model of Gulf War Illness. Toxicology and Applied Pharmacology, pages 115821.
Crossref
Crossref
Masoud Hashemi, Alireza Zali, Ebrahim Golmakani, Mohammad Hossein Delshad, Mahdi Shadnoush & Mohammad-Esmaeil Akbari. (2021) Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. DARU Journal of Pharmaceutical Sciences 29:1, pages 51-59.
Crossref
Crossref
Shelena Laws & Kelly Conright. (2019) Cancer-Related Incident Bone Pain #380. Journal of Palliative Medicine 22:11, pages 1468-1470.
Crossref
Crossref
Francesca Ricchini, Augusto Caraceni, Ernesto Zecca, Alessandra Pigni, Fabio Centurioni, Andrea Manzoni, Stein Kaasa & Cinzia Brunelli. (2019) Effect of Opioid Exposure on Efficacy and Tolerability of Sublingual Fentanyl and Subcutaneous Morphine for Severe Cancer Pain Episodes. Secondary Analysis From a Double-Blind Double-Dummy, Randomized Trial. Journal of Pain and Symptom Management 58:4, pages 587-595.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2019) Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. Drugs in R&D 19:3, pages 247-254.
Crossref
Crossref
Ayman Abdalmaksoud Yousef & Ashraf Elsayed Alzeftawy. (2018) The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study. Supportive Care in Cancer 27:6, pages 2171-2177.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2018) Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication. Drugs in R&D 18:2, pages 119-128.
Crossref
Crossref
Robert Janknegt, Marieke van den Beuken, Sjouke Schiere, Michael Überall, Roger Knaggs, Jaquie Hanley & Morten Thronaes. (2018) Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. European Journal of Hospital Pharmacy 25:3, pages e2-e2.
Crossref
Crossref
Noriko WADA, Yuka KASHIWABARA, Hitomi HIGUCHI, Miwa HINATA, Tadanori SASAKI & Yasuhisa KATO. (2018) Comparison of User Impressions of Oral Transmucosal Fentanyl Placebo Formulations by Medical Staff. The Showa University Journal of Medical Sciences 30:1, pages 53-62.
Crossref
Crossref
Michael A. Überall. (2017) Transmukosale Applikation von Fentanyl: sublingual, buccal, nasal — egal?Transmucosal fentanyl administration: sublingual, buccal, nasal — all the same? Treatment of breakthrough cancer pain. MMW - Fortschritte der Medizin 159:S6, pages 15-22.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Joan Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas, Antonio Javier Jiménez & Almudena Sanz. (2017) Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study. Drugs in R&D 17:3, pages 419-425.
Crossref
Crossref
Jeannine Brant, Barbara Rodgers, Eva Gallagher & Thiruppavai Sundaramurthi. (2017) Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
. Clinical Journal of Oncology Nursing 21:3, pages 71-80.
Crossref
Crossref
Stephan A. Schug & Sonya Ting. (2017) Fentanyl Formulations in the Management of Pain: An Update. Drugs 77:7, pages 747-763.
Crossref
Crossref
Saadya A. Tayel, Mohamed A. El Nabarawi, Maha M. Amin & Mohamed H. H. AbouGhaly. (2016) Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets. AAPS PharmSciTech 18:2, pages 410-423.
Crossref
Crossref
Norio Watanabe, Sachiko Hosokawa, Takuya Yamada, Chikako Yoshida, Akiko Suzuki, Naruhito Anbe, Masaya Ito, Ikie Niwa & Keiko Yamamura. (2017) A Survey of the Current Status of Fentanyl Sublingual Tablets and Evaluation of Problems Associated with Their Proper Use. An Official Journal of the Japan Primary Care Association 40:1, pages 27-32.
Crossref
Crossref
. (2016) ACMT Position Statement: Safety Issues Regarding Prescription Fentanyl Products. Journal of Medical Toxicology 12:2, pages 211-212.
Crossref
Crossref
Andrew Davies, Gill Mundin, Joanna Vriens, Kath Webber, Alison Buchanan & Melanie Waghorn. (2016) The Influence of Low Salivary Flow Rates on the Absorption of a Sublingual Fentanyl Citrate Formulation for Breakthrough Cancer Pain. Journal of Pain and Symptom Management 51:3, pages 538-545.
Crossref
Crossref
Jordi Guitart, María Isabel Vargas, Vicente De Sanctis, Jordi Folch, Rafael Salazar, José Fuentes, Jordi Coma, Julia Ferreras, Jordi Moya, Albert Tomás, Pere Estivill, Francisco Rodelas & Antonio Javier Jiménez. (2015) Sublingual Fentanyl Tablets for Relief of Breakthrough Pain in Cancer Patients and Association with Quality-of-Life Outcomes. Clinical Drug Investigation 35:12, pages 815-822.
Crossref
Crossref
Andrew Davies, Ulrich R. Kleeberg, Jerzy Jarosz, Sebastiano Mercadante, Philippe Poulain, Tony O’Brien, Hélène Schneid & Hans G. Kress. (2015) Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Supportive Care in Cancer 23:7, pages 2135-2143.
Crossref
Crossref
Luz Cánovas-Martínez, José J. Carceller-Ruiz, Pilar Díaz-Parada, Gustavo Illodo-Miramontes, Enrique Freire-Vila, Aurora De la Iglesia-López, Belén García Iglesias, Beatriz López-Ulloa, Enrique Domínguez-Suárez & Alberto Camba-Rodríguez. (2015) Efficacy and Safety of Sublingual Fentanyl Tablets for the Management of Breakthrough Pain in Patients with Chronic Musculoskeletal Pain with Neuropathic Component: Multicenter Prospective Study. Clinical Drug Investigation 35:3, pages 169-177.
Crossref
Crossref
C. Takigawa, F. Goto, S. Tanda, Y. Shima, K. Yomiya, M. Matoba, I. Adachi, T. Yoshimoto & K. Eguchi. (2014) Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation. Japanese Journal of Clinical Oncology 45:1, pages 67-74.
Crossref
Crossref
Ignacio Velázquez Rivera, José Carlos Muñoz Garrido, Pilar García Velasco, Inmaculada España Ximénez de Enciso & Lourdes Velázquez Clavarana. (2014) Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain. Advances in Therapy 31:1, pages 107-117.
Crossref
Crossref
Jordi Guitart, Isabel Vargas, Vicente De Sanctis, Julia Ferreras, Jose Fuentes, Rafael Salazar, Juan M. Vázquez, Jordi Folch, Jordi Moya, Hermann Ribera, Francisco Rodelas, Albert Tomás, María Arilla, Joan Coma, Teresa Aberasturi, Dolores Sintes & Ester Lombán. (2013) Efficacy and Safety of Sublingual Fentanyl Orally Disintegrating Tablets in Patients with Breakthrough Pain: Multicentre Prospective Study. Clinical Drug Investigation 33:9, pages 675-683.
Crossref
Crossref
Donald R TaylorDonald Taylor. 2013. Managing Cancer Breakthrough Pain. Managing Cancer Breakthrough Pain
29
66
.
C.I. Ripamonti, D. Santini, E. Maranzano, M. Berti & F. Roila. (2012) Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of Oncology 23, pages vii139-vii154.
Crossref
Crossref
C.I. Ripamonti. (2012) Pain management. Annals of Oncology 23, pages x294-x301.
Crossref
Crossref
Howard Smith. (2012) A Comprehensive Review of Rapid-Onset Opioids for Breakthrough Pain. CNS Drugs 26:6, pages 509-535.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Supportive & Palliative Care 6:1, pages 109-125.
Crossref
Crossref